ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| KATHERINE RAAB | — |
Medicare/Medicaid MMM
Medicare Part D Reform. H.R._/S._: Ensuring Access to Lower-Cost Medicines for Seniors Act. H.R._/S._: Increasing Access to Biosimilars Act. Medicaid Rebate Penalty.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| KATHERINE RAAB | — |
Copyright/Patent/Trademark CPT
H.R._/S._: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R._/S._: Patent Eligibility Restoration Act. H.R._/S._: To address patent thickets. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S._: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| KATHERINE RAAB | — |
Trade (domestic/foreign) TRD
General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| KATHERINE RAAB | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.